TIDMAVCT

RNS Number : 5835I

Avacta Group PLC

31 August 2016

31 August 2016

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Change of Registered Office

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, is pleased to announce that it has changed the address of its registered office to Unit 20, Ash Way, Thorp Arch Estate, Wetherby, LS23 7FA.

ENDS

Notes to Editors

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                           Tel: +44 (0) 
  Alastair Smith, Chief Executive            844 414 0452 
  Officer                                    www.avacta.com 
  Tony Gardiner, Chief Financial 
  Officer 
 Numis Securities Limited                   Tel: +44 (0) 
  Michael Meade / Freddie Barnfield          207 260 1000 
  - Nominated Adviser                        www.numiscorp.com 
  James Black - Corporate Broking 
 
  WG Partners                                Tel: +44 (0) 
  David Wilson                               203 705 9318 
  Nigel Barnes                               Tel: +44 (0) 
  Claes Spang                                203 705 9217 
                                             www.wgpartners.co.uk 
 
   FTI Consulting (Financial Media            Tel: +44 (0) 
   and IR)                                    203 727 1000 
   Simon Conway / Natalie Garland-Collins     avacta@fticonsulting.com

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.

Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CROSDMFDFFMSEFA

(END) Dow Jones Newswires

August 31, 2016 09:17 ET (13:17 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avacta Charts.